Acceptable risk in biomedical research : European perspectives
著者
書誌事項
Acceptable risk in biomedical research : European perspectives
（International library of ethics, law, and the new medicine, v. 50）
Springer, c2012
- : pbk
大学図書館所蔵 件 / 全3件
-
該当する所蔵館はありません
- すべての絞り込み条件を解除する
注記
"Softcover reprint of the hardcover 1st edition 2012"--T.p. verso of pbk
Includes bibliographical references (p. 279-290) and index
内容説明・目次
内容説明
This book is the first major work that addresses a core question in biomedical research: the question of acceptable risk. The acceptable level of risks is regulated by the requirement of proportionality in biomedical research law, which state that the risk and burden to the participant must be in proportion to potential benefits to the participant, society or science.
This investigation addresses research on healthy volunteers, children, vulnerable subjects, and includes placebo controlled clinical trials. It represents a major contribution towards clarifying the most central, but also the most controversial and complex issue in biomedical research law and bioethics. The EU Clinical Trial Directive, the Council of Europe's Oviedo Convention (and its Additional Protocol), and national regulation in member states are covered. It is a relevant work for lawyers and ethicists, and the practical approach makes a valuable tool for researchers and members of research ethics committees supervising biomedical research.
目次
1. Introduction
2. Method and material
3. Initial conceptual clarifications
4. Origins of the requirement of proportionality
5. The purpose of the requirement of proportionality
6. Introduction: Part II
7. Which risks, burdens and potential benefits are relevant?
8. How to estimate risks, burdens, and potential benefits
9. The requirement of proportionality - initial clarifications
10. Therapeutic research
11. Nontherapeutic research
12. Nontherapeutic research on "vulnerable" participants
13. Non-interference with necessary clinical interventions and the no harm rule
14. Especially on randomised clinical trials, including placebo controlled clinical trials
15. Acceptable Risks and Burdens to Others than the Participant
16. Later developments during the course of the research
17. Legal effects of the requirement of proportionality
18. Summary of results
19. Recommendations
20. Perspectives
21. Appendix
「Nielsen BookData」 より
